Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have been given a consensus recommendation of “Buy” by the eight brokerages that are currently covering the firm, Marketbeat reports. Three analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $19.00.
MCRB has been the subject of a number of research analyst reports. Zacks Investment Research raised Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price target for the company in a research note on Wednesday, July 5th. Cowen and Company reaffirmed a “buy” rating on shares of Seres Therapeutics in a research note on Friday, May 19th. Canaccord Genuity set a $20.00 price target on Seres Therapeutics and gave the stock a “buy” rating in a research note on Monday, June 12th. ValuEngine raised Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 1st. Finally, HC Wainwright reissued a “buy” rating and set a $19.00 price objective (up previously from $15.00) on shares of Seres Therapeutics in a research report on Friday, August 4th.
Institutional investors have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its position in Seres Therapeutics by 15.9% during the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after buying an additional 50,860 shares during the period. Goldman Sachs Group Inc. raised its position in shares of Seres Therapeutics by 24.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 44,418 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 8,851 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Seres Therapeutics by 5.8% in the 1st quarter. Geode Capital Management LLC now owns 166,325 shares of the biotechnology company’s stock worth $1,874,000 after purchasing an additional 9,060 shares during the last quarter. Citadel Advisors LLC raised its position in shares of Seres Therapeutics by 74.8% in the 1st quarter. Citadel Advisors LLC now owns 20,662 shares of the biotechnology company’s stock worth $233,000 after purchasing an additional 8,841 shares during the last quarter. Finally, Highbridge Capital Management LLC raised its position in shares of Seres Therapeutics by 104.0% in the 1st quarter. Highbridge Capital Management LLC now owns 30,843 shares of the biotechnology company’s stock worth $347,000 after purchasing an additional 15,726 shares during the last quarter. 74.76% of the stock is owned by institutional investors and hedge funds.
Seres Therapeutics (NASDAQ:MCRB) opened at 14.80 on Tuesday. The firm’s market cap is $599.58 million. Seres Therapeutics has a 52-week low of $8.85 and a 52-week high of $15.09. The company’s 50 day moving average is $13.62 and its 200-day moving average is $11.21.
Seres Therapeutics (NASDAQ:MCRB) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by $0.10. Seres Therapeutics had a negative return on equity of 80.21% and a negative net margin of 441.38%. The business had revenue of $3 million during the quarter, compared to analysts’ expectations of $3 million. During the same period in the previous year, the business earned ($0.70) EPS. The business’s revenue was up .0% compared to the same quarter last year. On average, equities analysts predict that Seres Therapeutics will post ($2.48) EPS for the current fiscal year.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.